Latest Breaking News On - American society for clinical oncology annual meeting - Page 1 : comparemela.com

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Western australiaUnited kingdomUnited statesClayton robertsonRyan sullivanAlexandra ikeguchiImmunocore immMohammed darPaul nathanRalph torbayImmunocore holdingsHead of communicationsEuropean unionExchange commissionAmerican society for clinical oncology annual meetingExchange commission on

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and
smdailyjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smdailyjournal.com Daily Mail and Mail on Sunday newspapers.

United kingdomWestern australiaUnited statesPaul nathanMohammed darImmunocore immRyan sullivanRalph torbayAlexandra ikeguchiAmerican society for clinical oncology annual meetingImmunocore holdingsEuropean unionClinical developmentAmerican societyClinical oncologySenior vice president

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Region flamandeSoult ukpyolsiSouth koreaUnited statesRepublic of koreaByoung chul choHenar heviaCraig tendlerAmerican lung associationSlate developmentJanssen cilag internationalAmerican society of clinical oncologyEuropean medicines agency seeking approvalJanssen cilag international nv incCommittee for medicinal products human useNational cancer institute

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

United statesShuntaro ikegawaDana farber cancer instituteDana farber instituteAmerican society for clinical oncology annual meetingClinical oncology annual meetingPatients with relapsed refractory multiple myelomaMultiple myelomaInternational myeloma society annual meetingPhase 1 trial nct04318327Durcabtagene autoleucel

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

/PRNewswire/ ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011.

United statesAmerican society for clinical oncology annual meetingClinical oncology annual meetingPoster discussionsCommon criteriaAdverse eventsSerious adverse eventOncolytic virusCancer vaccineBiosynthetic exosome